Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

OXIS International annonce la création d'une coentreprise avec engage:BDR.
OXIS International annonce la création d'une coentreprise avec engage:BDR.
OXIS International annonce la création d’une coentreprise avec engage:BDR, société leader mondiale de marketing numérique, dans le cadre du lancement au mois d’avril,
Actusnews 
0 18.04.12
OXIS International Announces Joint Venture With Global Leading Digital Marketing Firm engage:BDR to Launch New EGT(TM) Based Health and Nutrition Product Line in April
OXIS International Announces Joint Venture With Global Leading Digital Marketing Firm engage:BDR to Launch New EGT(TM) Based Health and Nutrition Product Line in April
Global Online Digital Campaign Reaching Target Audience of 109 Million Expected to Drive Significant Revenue BEVERLY HILLS, Calif., April 17, 2012 (GLOBE NEWSWIRE) -- OXIS International, Inc., (OTCBB:OXIS);
Actusnews 
0 17.04.12
Synergy Pharmaceuticals Achieves Halfway Mark in Enrollment on Plecanatide Phase II/III Trial in Chronic Idiopathic Constipation
Synergy Pharmaceuticals Achieves Halfway Mark in Enrollment on Plecanatide Phase II/III Trial in Chronic Idiopathic Constipation
NEW YORK, April 9, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) (Nasdaq:SGYPU) (Nasdaq:SGYPW), a developer of new drugs to treat gastrointestinal disorders and diseases, today
Actusnews 
0 09.04.12
ERGOFLEX(TM) Joint Pain Study Published Online in Preventive Medicine
ERGOFLEX(TM) Joint Pain Study Published Online in Preventive Medicine
OXIS International's Proprietary ERGOFLEX Product Demonstrates Significant Improvement in Pain and Range of Motion -- Product Launch 2nd Quarter 2012 BEVERLY HILLS, Calif., March 28, 2012 (GLOBE
Actusnews 
0 29.03.12
ERGOFLEX(TM) Étude sur les douleurs articulaires publiée en ligne dans " Preventive Medicine "
ERGOFLEX(TM) Étude sur les douleurs articulaires publiée en ligne dans " Preventive Medicine "
Le produit exclusif d'OXIS International, ERGOFLEX, permet des améliorations significatives au niveau des douleurs et de l'amplitude des mouvements – Le lancement du produit est
Actusnews 
0 29.03.12
OXIS International reçoit un engagement financier de 1 million USD pour appuyer le lancement de sa ligne exclusive de produits
OXIS International reçoit un engagement financier de 1 million USD pour appuyer le lancement de sa ligne exclusive de produits
Les investisseurs d’OXIS témoignent de leur confiance dans la capacité de la nouvelle équipe de direction à réussir le lancement de sa nouvelle ligne de produits
Actusnews 
0 22.03.12
OXIS International Receives 1 USD Million Funding Commitment to Support April Launch of Proprietary Product Line
OXIS International Receives 1 USD Million Funding Commitment to Support April Launch of Proprietary Product Line
OXIS Investors Show Confidence in New Management's Ability to Successfully Begin Product Line Launch in April BEVERLY HILLS, Calif., March 21, 2012 (GLOBE NEWSWIRE) -- OXIS International, Inc., (OTCBB:OXIS)
Actusnews 
0 21.03.12
Oxis International Adds Senior Marketing and Product Innovation Executive to Management Team
Oxis International Adds Senior Marketing and Product Innovation Executive to Management Team
Addition of Suzy Couturier to Oxis Senior Executive Team Opens Door to Rapid Development and Introduction of New Ergothioneine Based Products Into the Natural Skin Care and Dietary Supplement Sectors
Actusnews 
0 06.01.12
Oxis International intègre une directrice marketing et innovation produits à son équipe dirigeante
Oxis International intègre une directrice marketing et innovation produits à son équipe dirigeante
L'arrivée de Suzy Couturier au sein de l'équipe dirigeante d'Oxis ouvre la voie au développement rapide et au lancement de nouveaux produits à base d'ergothionéine
Actusnews 
0 06.01.12
Oxis International Inc. reçoit le statut G.R.A.S. pour son antioxydant breveté, le L-Ergothioneine
Oxis International Inc. reçoit le statut G.R.A.S. pour son antioxydant breveté, le L-Ergothioneine
Le rapport ouvre la voie à Oxis pour développer une gamme complète de compléments nutritionnels, d’aliments et de boissons fonctionnels et de produits de soins personnels
Actusnews 
0 10.10.11
Oxis International Inc. Receives GRAS Status for Its Patented L-Ergothioneine Anti-Oxidant
Oxis International Inc. Receives GRAS Status for Its Patented L-Ergothioneine Anti-Oxidant
Report Clears Path for Oxis to Develop Full Line of Dietary Supplements, Functional Foods and Beverages, and Personal Care Products BEVERLY HILLS, Calif., Oct. 10, 2011 (GLOBE NEWSWIRE) -- Oxis International
Actusnews 
0 10.10.11
Why Celldex Therapeutics Blasted 13% Higher on Monday: https://g.foolcdn.com/editorial/images/754016/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg
Why Celldex Therapeutics Blasted 13% Higher on Monday

Clinical-stage biotech Celldex Therapeutics (NASDAQ: CLDX) was a standout on the stock market Monday. The company's share price closed a sturdy 13% higher on the day, thanks to freshly published

TheMotleyFool 
0 07.11.23
IVERIC bio: NBC-Mitglieder nehmen +41% Kursgewinn mit
IVERIC bio: NBC-Mitglieder nehmen +41% Kursgewinn mit

Schon 2019 hat IVERIC bio (WKN: A2PHLF) den NBC-Klingelbeutel mit sagenhaften +486% in wenigen Wochen erheblich beschwert. Nach einigen Monaten in einer Seitwärtsphase konnten Mitglieder des

sharedeals 
0 21.09.20
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference


Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced

BusinessWire_EN 
0 07.05.24
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue


Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced

BusinessWire_EN 
0 25.04.24
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological

BusinessWire_EN 
0 09.04.24
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological

BusinessWire_EN 
0 01.04.24
Vistagen to Present at Stifel 2024 Virtual CNS Days: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at Stifel 2024 Virtual CNS Days


Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced

BusinessWire_EN 
0 11.03.24
Vistagen to Present at TD Cowen 44th Annual Health Care Conference: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at TD Cowen 44th Annual Health Care Conference


Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced

BusinessWire_EN 
0 28.02.24
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported

BusinessWire_EN 
0 13.02.24
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024


Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today announced it

BusinessWire_EN 
0 06.02.24
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

BusinessWire_EN 
0 27.12.23
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

BusinessWire_EN 
0 09.11.23
Vistagen to Present at Stifel 2023 Healthcare Conference: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present at Stifel 2023 Healthcare Conference


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

BusinessWire_EN 
0 08.11.23
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences


Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

BusinessWire_EN 
0 07.11.23